Literature DB >> 26290187

Redundancy complicates the definition of essential genes for vaccinia virus.

Bianca M Dobson1, David C Tscharke2,1.   

Abstract

Vaccinia virus (VACV) genes are characterized as either essential or non-essential for growth in culture. It seems intuitively obvious that if a gene can be deleted without imparting a growth defect in vitro it does not have a function related to basic replication or spread. However, this interpretation relies on the untested assumption that there is no redundancy across the genes that have roles in growth in cell culture. First, we provide a comprehensive summary of the literature that describes the essential genes of VACV. Next, we looked for interactions between large blocks of non-essential genes located at the ends of the genome by investigating sets of VACVs with large deletions at the genomic termini. Viruses with deletions at either end of the genome behaved as expected, exhibiting only mild or host-range defects. In contrast, combining deletions at both ends of the genome for the VACV Western Reserve (WR) strain caused a devastating growth defect on all cell lines tested. Unexpectedly, we found that the well-studied VACV growth factor homologue encoded by C11R has a role in growth in vitro that is exposed when 42 genes are absent from the left end of the VACV WR genome. These results demonstrate that some non-essential genes contribute to basic viral growth, but redundancy means these functions are not revealed by single-gene-deletion mutants.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26290187      PMCID: PMC5972330          DOI: 10.1099/jgv.0.000266

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.

Authors:  Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

2.  Poxviruses package viral redox proteins in lateral bodies and modulate the host oxidative response.

Authors:  Susanna R Bidgood; Jerzy Samolej; Karel Novy; Abigail Collopy; David Albrecht; Melanie Krause; Jemima J Burden; Bernd Wollscheid; Jason Mercer
Journal:  PLoS Pathog       Date:  2022-07-14       Impact factor: 7.464

3.  Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.

Authors:  Baoming Liu; Debasis Panda; Jorge D Mendez-Rios; Sundar Ganesan; Linda S Wyatt; Bernard Moss
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.

Authors:  Ruikang Liu; Jorge D Mendez-Rios; Chen Peng; Wei Xiao; Andrea S Weisberg; Linda S Wyatt; Bernard Moss
Journal:  PLoS Pathog       Date:  2019-05-30       Impact factor: 6.823

5.  A poxvirus pseudokinase represses viral DNA replication via a pathway antagonized by its paralog kinase.

Authors:  Annabel T Olson; Zhigang Wang; Amber B Rico; Matthew S Wiebe
Journal:  PLoS Pathog       Date:  2019-02-15       Impact factor: 6.823

6.  Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy.

Authors:  Adrian Pelin; Johann Foloppe; Julia Petryk; Ragunath Singaravelu; Marian Hussein; Florian Gossart; Victoria A Jennings; Lawton J Stubbert; Madison Foster; Christopher Storbeck; Antonio Postigo; Elena Scut; Brian Laight; Michael Way; Philippe Erbs; Fabrice Le Boeuf; John C Bell
Journal:  Mol Ther Oncolytics       Date:  2019-07-03       Impact factor: 7.200

Review 7.  Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Authors:  A Volz; G Sutter
Journal:  Adv Virus Res       Date:  2016-08-01       Impact factor: 9.937

8.  Rapid poxvirus engineering using CRISPR/Cas9 as a selection tool.

Authors:  Anjali Gowripalan; Stewart Smith; Tijana Stefanovic; David C Tscharke
Journal:  Commun Biol       Date:  2020-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.